Quality Assurance Measures at Myriad Genetics

Ninety-three percent of test orders received at Myriad are clinically appropriate, meeting the 2012 NCCN Guidelines® genetic test criteria, MFAP medical criteria or both. This is in contrast to a report published in March of 2011, which states that inappropriately ordered tests represent “approximately 30% of all complex genetic tests ordered”.15 One reason for the higher percentage of clinically appropriate test orders received at Myriad may be that the current report includes only test orders for BRACAnalysis and COLARIS, tests for the two most common hereditary cancer syndromes, whereas the report published in 201115 included data for orders of 38 different “complex biochemical, cytogenetic, and molecular genetic tests.”

Given the fact that both HBOC and Lynch Syndrome have established testing criteria and medical management guidelines, healthcare providers are likely more familiar with these syndromes and therefore less likely to inaccurately order these tests.4-7

In addition, Myriad employs a team of field-based MS employees who proactively provide hereditary cancer education regarding established risk factors and medical management guidelines. This educational outreach effort may increase healthcare provider interest and knowledge of hereditary cancer syndromes in comparison to rare conditions included in the aforementioned report, leading to a higher percentage of appropriately ordered tests at Myriad.

Download the white paper.